- Home
- SAGU vs BDTX Comparison
SAGU vs BDTX Comparison
Compare SAGU & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SAGU | BDTX |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | Mauritius | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.1M | 171.9M |
| IPO Year | 2025 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SAGU | BDTX |
|---|---|---|
| Price | $10.07 | $1.84 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $10.00 |
| AVG Volume (30 Days) | 25.7K | ★ 568.9K |
| Earning Date | N/A | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 130.71 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.88 | $1.60 |
| 52 Week High | $10.07 | $4.94 |
Technical Indicators
Market Signals| Indicator | SAGU | BDTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.32 | 41.03 |
| Support Level | $9.95 | $1.76 |
| Resistance Level | $10.05 | $1.90 |
| Average True Range (ATR) | 0.02 | 0.09 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 63.64 | 24.49 |
Price Performance
Historical ComparisonAbout SAGU Shreya Acquisition Group Class A Ordinary Shares
Shreya Acquisition Group is a blank check company.
About BDTX Black Diamond Therapeutics Inc.
Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.